文献速递炎症性肠病

溃疡性结肠炎临床试验终点定义异质性:为制定核心结局指标集的系统评价

Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-08-24

该系统评价检索了截至2017年3月1日的安慰剂对照随机对照试验,纳入83项试验共17737例溃疡性结肠炎患者。结果显示临床或复合临床疗效终点的定义存在超过50种应答或缓解定义,内镜、组织学和生物标志物终点使用比例分别为83.1%、24.1%和24.1%,组织学和生物标志物终点缺乏标准化定义。作者建议确定核心结局集以标准化疗效和安全性报告。

要点

  • 83项安慰剂对照随机对照试验中,临床或复合临床疗效终点定义存在超过50种应答或缓解定义。
  • 内镜、组织学和生物标志物终点分别用于83.1%、24.1%和24.1%的试验。
  • 2007年后发表的试验更多报告客观终点,但组织学和生物标志物终点无标准化定义。

核心结论

  • 尽管临床试验方法近期有进展,溃疡性结肠炎随机对照试验中终点定义(包括应答和缓解)仍存在很大差异,研究者应确定核心结局集以标准化疗效和安全性报告。

研究设计与样本

  • 系统评价,检索MEDLINE、EMBASE和Cochrane Library自建库至2017年3月1日,纳入83项安慰剂对照随机对照试验(68项诱导试验和15项维持试验),共17737例溃疡性结肠炎患者。

主要发现

  • 所有试验均报告临床或复合临床疗效终点,UC疾病活动指数和Mayo Clinic评分常用于判定临床应答或缓解,但应答或缓解定义超过50种。
  • 内镜、组织学和粪便或血清生物标志物用于判定结局的试验比例分别为83.1%(69/83)、24.1%(20/83)和24.1%(20/83)。
  • 2007年后发表的试验中,报告客观结局的比例更高(内镜96.5%、组织学26.3%、生物标志物36.8%),但未发现组织学或生物标志物终点的标准化定义。
  • 患者报告疗效和生活质量结局在25项试验(30.1%)中描述,安全性结局在77项试验(92.8%)中报告。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Advances in development of therapeutic agents for ulcerative colitis (UC) have been paralleled by innovations in trial design. It would be useful to identify a core outcome set, to standardize outcome definitions for efficacy and safety in clinical trials. We performed a systematic review of efficacy and safety outcomes reported in placebo-controlled randomized controlled trials of patients with UC. METHODS: We searched MEDLINE, EMBASE, and the Cochrane Library from inception through March 1, 2017, for placebo-controlled randomized controlled trials of adult patients with UC treated with aminosalicylates, immunosuppressants, corticosteroids, biologics, and oral small molecules. We collected information on efficacy and safety outcomes, definitions, and measurement tools, stratified by decade of publication. RESULTS: We analyzed data from 83 randomized controlled trials (68 induction and 15 maintenance) comprising 17,737 patients. Clinical or composite-clinical efficacy outcomes were reported in all trials; the UC Disease Activity Index and Mayo Clinic Score were frequently used to determine clinical response or remission. We found substantial variation in definitions of clinical or composite-clinical endpoints, with more than 50 definitions of response or remission. Endoscopic factors, histologic features, and fecal or serum biomarkers were used to determine outcomes in 83.1% (69 of 83), 24.1% (20 of 83), and 24.1% (20 of 83) of trials, respectively. A greater proportion of trials published after 2007 reported objective outcomes (96.5% endoscopic, 26.3% histologic, and 36.8% biomarker outcomes), but no standardized definitions of histologic or biomarker endpoints were found. Patient-reported efficacy and quality-of-life outcomes were described in 25 trials (30.1%) and safety outcomes were reported in 77 trials (92.8%). CONCLUSION: In a systematic review, we found that despite recent advances in clinical trials methods, there is a great deal of variation in definitions of endpoints, including response and remission, in randomized controlled trials of patients with UC. Researchers should identify a core set of outcomes to standardize efficacy and safety reporting in UC clinical trials.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ma C, Panaccione R, Fedorak RN, et al. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2017. PMID: 28843356. doi:10.1016/j.cgh.2017.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。